Cardiovascular disease is the leading cause of death across most of the world. It is estimated that up to 90% of deaths are preventable. Statins are a class of lipid-lowering pharmaceuticals, and are among the most widely prescribed class of drugs. Statins have been found to reduce cardiovascular disease and mortality in those who are at high risk, but also are associated with unwanted side effects. Statin+ may provide a safer, more effective therapy to current and new users unable to currently take a Statin.
Side effects of statins include muscle pain, increased risk of diabetes mellitus, and abnormalities in liver enzyme tests. Other possible adverse effects include cognitive loss, neuropathy, pancreatic and hepatic dysfunction, and sexual dysfunction. In observational studies 10-15% of people who take statins experience muscle problems; in most cases these consist of muscle pain. Statins are also associated with a slightly increased risk of diabetes (2-17% in one review.) Additionally, about half of all first time statin patients discontinue due to adverse effects, and require being re-challenged with statin, adding costs and risks.
The Statin+ concept combines an existing FDA-approved small molecule to existing statin drugs. This combination is expected to demonstrate synergistic effects of improved lipid lowering, reduction of arterial plaque, and reduction of side-effects. Please contact us for detailed information of the Statin+ platform.
Copyright © 2023 Indication BioScience, LLC - All Rights Reserved.